Filter posts

Fireside Chat with Allergan CEO, David Pyott

Day two of the 16th Annual BIO CEO & Investor Conference​ kicked off with a Fireside Chat featuring one …

Open Communication Helps Reduce Rare Disease Drug Development Risk

One of the most important keys to successful relationships – be it in life or …

Sanofi’s Chris Viehbacher: Trust, Respect Key in Pharma-Biotech Partnerships

How can large pharmaceutical and small biotech companies form mutually beneficial partnerships that harness the …

What's New in RNAi Therapeutics?

At the 16th Annual BIO CEO & Investor Conference​, Monday morning’s therapeutic workshop, “Delivering the (RNAi) …

4 Tips for Building a Successful Biotech: Richard Pops of Alkermes at #BIOCEO14

The 16th Annual BIO CEO & Investor Conference opened with a fireside chat between Richard …

Biotech Investors, Emerging Companies Bullish On 2014

The 16th BIO CEO & Investor Conference is off to a great start. This event …

Buy Side Investors Bullish Ahead of 2014 BIO CEO & Investor Conference

2013 was a record year for the biotech sector, with the NASDAQ Biotechnology Index hitting …

BIO CEO Company Snapshot: Tetraphase Pharmaceuticals

The BIO CEO & Investor Conference is now just a week away, and buzz for …

2013 Novel Drug Approvals

The FDA approved 24 novel drugs last year by our count, in line with average …

More than a Quarter of 2013 US-Based Biotech IPOs Call California Home

And of those 39 US-based biotech companies, five of them are from San Diego, highlighting …